Literature DB >> 21540649

Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients.

Liljana Mervic1, Ulrike Leiter, Friedegund Meier, Thomas Eigentler, Andrea Forschner, Gisela Metzler, Igor Bartenjev, Petra Büttner, Claus Garbe.   

Abstract

This study identified sex differences in clinical presentation and survival for primary cutaneous melanoma without clinical evidence of metastasis at diagnosis from 1976 to 2008 in southern Germany. Melanoma-specific survival curves and estimated survival probabilities were generated using the Kaplan-Meier method. Multivariate survival analyses were carried out using the Cox modeling. Male patients had significantly thicker and more frequently ulcerated tumors and a lower 10-year disease-specific survival (DSS) and recurrence-free survival probability compared with females among patients of 43 years old or younger (DSS: 86.1 vs. 93.2%, P<0.001) and 44-60 years old (DSS: 83.5 vs. 90.1%, P<0.001). The survival advantage of female patients in terms of 10-year DSS and 10-year recurrence-free survival was not observed after an age of 60 years (P=0.21 and 0.51, respectively). Sex was of prognostic importance for DSS and survival after recurrence [hazards ratio (HR): 1.3; 95% confidence interval (CI): 1.1-1.6; P=0.002 and HR: 1.2; 95% CI: 1.0-1.5; P=0.018, respectively]. Stratified by age groups, sex remained of prognostic importance for DSS only in patients of 43 years or younger, and 44-60 years old (HR: 1.5; 95% CI: 1.0-2.1; P=0.03 and HR: 1.4; 95% CI: 1.1-2.0; P=0.02, respectively). Sex is an independent prognostic factor in surviving melanoma. The sex difference in survival with a better outcome for women is confined to melanoma patients of 60 years and younger. In addition, in younger age groups, male patients present with prognostically unfavorable features of primary melanoma. A female survival advantage is also known for other solid tumors such as colon and lung cancer; however, age dependency has not been studied.

Entities:  

Mesh:

Year:  2011        PMID: 21540649     DOI: 10.1097/CMR.0b013e32834577c8

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  19 in total

1.  Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort.

Authors:  Tina J Hieken; Amy E Glasgow; Elizabeth Ann L Enninga; Lisa A Kottschade; Roxana S Dronca; Svetomir N Markovic; Matthew S Block; Elizabeth B Habermann
Journal:  J Womens Health (Larchmt)       Date:  2020-02-27       Impact factor: 2.681

2.  Impact of age on the management of primary melanoma patients.

Authors:  Nathaniel H Fleming; Jiaying Tian; Eleazar Vega-Saenz de Miera; Heidi Gold; Farbod Darvishian; Anna C Pavlick; Russell S Berman; Richard L Shapiro; David Polsky; Iman Osman
Journal:  Oncology       Date:  2013-08-30       Impact factor: 2.935

Review 3.  Personalized therapy for metastatic melanoma: could timing be everything?

Authors:  Roxana S Dronca; Alexey A Leontovich; Wendy K Nevala; Svetomir N Markovic
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

4.  Effect of biology on the outcome of female melanoma patients.

Authors:  Kayhan Erturk; Faruk Tas
Journal:  Mol Clin Oncol       Date:  2017-10-09

5.  De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.

Authors:  Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky
Journal:  J Natl Cancer Inst       Date:  2016-05-27       Impact factor: 13.506

6.  Gender differences, UV exposure and risk of lentigo maligna in a nationwide healthcare population cohort study.

Authors:  H W Higgins; E Cho; M A Weinstock; T Y Li; A Qureshi; W Q Li
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-12-05       Impact factor: 6.166

Review 7.  Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.

Authors:  Amy A Mrazek; Celia Chao
Journal:  Surg Clin North Am       Date:  2014-08-05       Impact factor: 2.741

8.  Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study.

Authors:  Marie Fridberg; Liv Jonsson; Julia Bergman; Björn Nodin; Karin Jirström
Journal:  Biol Sex Differ       Date:  2012-07-02       Impact factor: 5.027

9.  Time course and pattern of metastasis of cutaneous melanoma differ between men and women.

Authors:  Liljana Mervic
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

10.  Cross-sectional study of sex differences in psychosocial quality of life of long-term melanoma survivors.

Authors:  Rachel I Vogel; Broderick Yoerg; Patricia I Jewett; Nathan Rubin; Megan Olson; Ashley E Stenzel; Rehana L Ahmed; DeAnn Lazovich
Journal:  Support Care Cancer       Date:  2021-02-12       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.